Loading company…
Shenzhen Xiankangda Life Science develops biopharmaceutical technologies and cell immunotherapies.
Shenzhen Xiankangda Life Science develops biopharmaceutical platforms and research programs in CAR-T, CAR-NK and iPSC-T. Its work includes cell immunotherapy, gene technology and stem cell products. Established in 2020, the company is based in Shenzhen, China, and raised pre-Series A funding from Lianjin Capital in May 2023 to advance clinical studies and IND filings for solid tumor CAR-T drugs.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in